All In Biotech

Drug Trial Radar · NCT07854509

A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure

A Phase II Clinical Study to Evaluate Sacituzumab Tirumotecan (SKB264) in Combination With SKB118 for the Treatment of EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer in Participants Who Have Failed Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Dec 30, 2027

Study completion Dec 30, 2029

Sponsor

Sponsor type
Industry
First posted
Oct 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitizing mutations who have failed EGFR-TKI therapy. The study includes a dose escalation phase and an expansion phase.

Conditions

  • Non-Squamous Non-Small Cell Lung Cancer

Interventions

  • SKB264+SKB118Drug

    Administered by intravenous infusion on Day 1 and Day 15 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety of SKB264 in combination with SKB118 in participants with non-squamous non-small cell lung cancer (NSCLC)Time frame: From enrollment to the end of treatment at 24 months
  2. ORR(objective response rate)Time frame: From enrollment to the end of treatment at 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.